{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-113159","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2024-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.055723+00:00","generated_at":"2026-05-28T23:08:03.434266+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025","bullets":["Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.","FDA approved LYMPHIR for relapsed/refractory CTCL; commercial launch planned H1 2025.","Pre-commercial activities: J-code application, NCCN inclusion, CSO recruitment, inventory built.","R&D $4.9M, G&A $8.1M, stock-based comp $7.5M vs $4.2M, $5.9M, $2.0M YoY.","Phase I combo with pembrolizumab showed 27% ORR, 33% CBR, median PFS 57 weeks in gynecological tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-113159","json":"https://secwatch.observer/filing/0001213900-24-113159.json","markdown":"https://secwatch.observer/filing/0001213900-24-113159.md","text":"https://secwatch.observer/filing/0001213900-24-113159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/0001213900-24-113159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/ea0226165-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:08:03.434266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}